ibn_169.jpg
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024
05 août 2024 08h00 HE | InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce...
ANVS logo.jpg
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
24 juil. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...
ANVS logo.jpg
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
16 juil. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ANVS logo.jpg
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
09 juil. 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo Figure 1
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
02 juil. 2024 08h00 HE | Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson’s patients with substantial cognitive decline exhibited a...
ANVS logo.jpg
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
27 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ANVS logo.jpg
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ANVS logo.jpg
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
25 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
ANVS logo.jpg
Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
18 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Picture4
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 juin 2024 08h00 HE | Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...